MED Raises Humana (HUM) Price Target to $373.00

Humana (NYSE:HUM) had its target price boosted by stock analysts at MED from $350.00 to $373.00 in a research note issued on Thursday, The Fly reports. The brokerage presently has an “outperform” rating on the insurance provider’s stock. MED’s target price suggests a potential upside of 9.62% from the stock’s current price.

A number of other equities analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Humana from a “buy” rating to a “hold” rating in a research note on Friday, October 5th. SunTrust Banks upped their price target on shares of Humana to $380.00 and gave the stock a “hold” rating in a research note on Wednesday, September 19th. Cowen began coverage on shares of Humana in a research note on Monday, September 17th. They issued a “market perform” rating and a $372.00 price target on the stock. Barclays began coverage on shares of Humana in a research note on Thursday, September 13th. They issued an “overweight” rating and a $370.00 price target on the stock. Finally, Credit Suisse Group upped their price target on shares of Humana from $350.00 to $370.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 4th. Seven investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $352.30.

Humana stock traded up $0.68 during mid-day trading on Thursday, reaching $340.27. The stock had a trading volume of 18,125 shares, compared to its average volume of 605,449. The stock has a market cap of $45.71 billion, a price-to-earnings ratio of 29.01, a PEG ratio of 1.65 and a beta of 1.03. Humana has a one year low of $231.90 and a one year high of $355.88. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.43.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.29 by $0.29. The company had revenue of $14.21 billion for the quarter, compared to analysts’ expectations of $13.97 billion. Humana had a net margin of 2.48% and a return on equity of 17.43%. During the same quarter in the previous year, the business posted $3.39 EPS. On average, equities analysts expect that Humana will post 14.44 EPS for the current fiscal year.

In other Humana news, CEO Bruce D. Broussard sold 18,000 shares of the business’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $328.66, for a total value of $5,915,880.00. Following the completion of the transaction, the chief executive officer now owns 71,085 shares of the company’s stock, valued at approximately $23,362,796.10. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Elizabeth D. Bierbower sold 3,092 shares of the business’s stock in a transaction dated Thursday, August 16th. The stock was sold at an average price of $330.00, for a total value of $1,020,360.00. Following the completion of the transaction, the insider now directly owns 14,289 shares of the company’s stock, valued at approximately $4,715,370. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by insiders.

Large investors have recently modified their holdings of the business. Stratos Wealth Partners LTD. purchased a new stake in shares of Humana during the 3rd quarter valued at about $108,000. Sun Life Financial INC increased its position in shares of Humana by 120.7% during the 2nd quarter. Sun Life Financial INC now owns 373 shares of the insurance provider’s stock valued at $111,000 after purchasing an additional 204 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Humana by 2,984.6% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 401 shares of the insurance provider’s stock valued at $119,000 after purchasing an additional 388 shares during the last quarter. Smithfield Trust Co. increased its position in shares of Humana by 531.2% during the 3rd quarter. Smithfield Trust Co. now owns 486 shares of the insurance provider’s stock valued at $165,000 after purchasing an additional 409 shares during the last quarter. Finally, Girard Partners LTD. purchased a new stake in shares of Humana during the 3rd quarter valued at about $169,000. 92.62% of the stock is owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Featured Article: How Do You Calculate Return on Investment (ROI)?

The Fly

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply